Denmark· DK-28107060023
Ofev
A nintedanib product containing nintedanibesilat, registered in Denmark by Boehringer Ingelheim Int. GmbH. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Nintedanib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EX09 (nintedanib), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 7 of them publish a price we can compare per daily dose
Nintedanib · ATC L01EX09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of nintedanib costs, country by country.
Normalised to the WHO defined daily dose (0.38 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Nintedanib · price per daily dose (0.38 g)
USD · FX 28 Sept 2026
- US United States$51.13 (acquisition cost)
- CH Switzerland$34.12
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Nintedanibesilat
- Manufacturer
- Boehringer Ingelheim Int. GmbH
- Country
- Denmark (DK)
- ATC code
- L01EX09
- ATC class
- Nintedanib
- Defined daily dose
- 0.38 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107060023
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
160 interactions on record for nintedanib.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nintedanib · interactions on record
160 records
- 21 severe
- 139 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- DexamethasoneH02AB02severe
- RifampicinJ04AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EX09
Nintedanib, as other registers publish it.
- IcelandAgarfNorameda UAB
- IcelandAgarfNorameda UAB
- NetherlandsGevesla 100 mg, zachte capsulesSandoz B.V.
- NetherlandsGevesla 150 mg, zachte capsulesSandoz B.V.
- IcelandLUNIDOCAdalvo Competence Center S.R.L.
- IcelandLUNIDOCAdalvo Competence Center S.R.L.
- IcelandNifibDEMO S.A PHARMACEUTICAL INDUSTRY
- IcelandNifibDEMO S.A PHARMACEUTICAL INDUSTRY
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cbe6f444-d5be-4261-9a48-9b04bb159a1a GET /v1/drugs/cbe6f444-d5be-4261-9a48-9b04bb159a1a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "kapsler, bløde",
"source": "dkma",
"strength": "25 mg",
"auth_role": "MOD",
"dk_drugid": "28107060023",
"substance": "Nintedanibesilat",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "45700"
}See everything about nintedanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.